A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma

Abstract

Although much focus has been placed on immunotherapy for melanoma, further development of chemotherapy approaches is needed. Melanoma is responsive to platinum compounds and taxanes, but there is limited experience with combinations of these agents. Oxaliplatin has been reported to have detectable activity in melanoma, and a phase I study has identified a… (More)
DOI: 10.1007/s00280-009-1057-y

Topics

4 Figures and Tables

Cite this paper

@article{Locke2009API, title={A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma}, author={Frederick L Locke and Joseph Clark and Thomas F Gajewski}, journal={Cancer Chemotherapy and Pharmacology}, year={2009}, volume={65}, pages={509-514} }